

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities.

*This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities referred to herein will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), and may not be offered or sold in the United States except pursuant to an exemption from, or a transaction not subject to, the registration requirements of the Securities Act. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer and its management and financial statements. The Company does not intend to make any public offering of securities in the United States.*



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING
OF
WUXI XDC CAYMAN INC. ON THE MAIN BOARD OF THE STOCK
EXCHANGE OF HONG KONG LIMITED**

POST HEARING INFORMATION PACK

Reference is made to the announcements of the Company dated July 9, 2023 and October 20, 2023 (the “**Announcements**”) in relation to the Proposed Spin-off and separate listing of the SpinCo, a subsidiary of the Company, on the Main Board of the Stock Exchange. Unless otherwise specified, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

POST HEARING INFORMATION PACK

The Board has been informed by the SpinCo that in connection with the Proposed Spin-off and the Global Offering, the SpinCo has submitted the post hearing information pack (the “PHIP”) to the Stock Exchange for publication on the Stock Exchange’s website. The PHIP is expected to be available for viewing and downloading from the website of the Stock Exchange at <http://www.hkexnews.hk/app/sehkappmainindex.htm>.

The PHIP contains, among other things, certain business and financial information relating to the SpinCo and its subsidiaries. Shareholders and other investors should note that the PHIP is in draft form and the information contained in the PHIP is incomplete and is subject to change which can be material. Shareholders and other investors are advised to refer to the Stock Exchange’s website at <http://www.hkexnews.hk/app/sehkappmainindex.htm> from time to time for any updated information which may be published by the SpinCo as and when appropriate. The Company does not have any obligation or liability whatsoever in relation to the PHIP or such other information published by the SpinCo.

GENERAL

Details in respect of the Proposed Spin-off, including the structure and the expected timetable, have yet to be finalized. Further announcement(s) will be made by the Company in relation to the Proposed Spin-off as and when appropriate in accordance with the Listing Rules.

As the Proposed Listing is conditional upon, among other things, the approval of the Listing Committee, the final decision of the Board and the board of directors of the SpinCo, market conditions and other considerations, the Proposed Spin-off may or may not materialize. Shareholders and other investors should be aware that there is no assurance that the Proposed Spin-off will take place or as to when it may take place. If the Proposed Spin-off does not proceed for any reason, the Preferential Offering will not proceed. Shareholders and other investors are reminded to exercise caution when dealing in the securities of the Company. Any person who is in doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional advisers.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, October 29, 2023

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.

* *For identification purpose only*